Netherlands’ Argenx Q3 sales jump on strong VYVGART demand – TradingView – EUROP INFO

Netherlands-based biopharmaceutical company Argenx reported a significant surge in third-quarter sales, driven primarily by robust demand for its flagship drug, VYVGART. The strong performance underscores growing market confidence in the company’s innovative autoimmune therapy and marks a pivotal milestone in Argenx’s commercial expansion. Investors responded positively, with the company’s stock gaining momentum on TradingView following the impressive quarterly results.